The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose Level.
Castillo, M. J.; Scheen, André; Lefebvre, Pierre
1996 • In Journal of Clinical Endocrinology and Metabolism, 81 (5), p. 1975-8
[en] This study aims at investigating the influence of the prevailing blood glucose level on the metabolic deterioration that follows a nocturnal interruption of a continuous sc insulin infusion (CSII). Fifteen CSII-treated, C-peptide negative, diabetic patients have been studied CSII was interrupted from 2300 h to 0500 h. Blood was collected hourly from 2200 h to 0600 h. According to blood glucose (BG) levels at 2300 h, patients were classified as hypoglycemic (BG between 1.5 and 2.5 mmol/L, n = 5), normoglycemic (BG between 4.0 and 8.0 mmol/L, n = 5), or hyperglycemic (BG between 9.0 and 15.0 mmol/L, n = 5). At 2300 h, BG (mean +/- SEM) was 1.9 +/- 0.1, 6.2 +/- 0.7 and 11.2 +/- 1.0 mmol/L, respectively. After 6 h of CSII interruption, BG increased to 13.5 +/- 1.3, 14.1 +/- 1.2, and 19.4 +/- 1.2 mmol/L, respectively. At 2300 h, plasma 3-OH-butyrate levels were similar in the three groups (around 150 micromol/L). At 0500 h, significantly higher values were obtained for hyperglycemic (1460 +/- 127 micromol/L) than for normoglycemic (868 +/- 150 micromol/L) or hypoglycemic (837 +/- 80 micromol/L) patients. Enhanced lipolysis in initially hyperglycemic patients may contribute to accelerated ketogenesis and metabolic degradation. In conclusion, the metabolic deterioration that follows CSII interruption is influenced by the initial metabolic situation. Hypoglycemic patients deteriorate more rapidly, and hyperglycemic patients suffer a more important degradation. The latter are prone to rapid ketoacidosis if accidental CSII interruption occurs.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Castillo, M. J.
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Lefebvre, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
English
Title :
The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose Level.
Publication date :
1996
Journal title :
Journal of Clinical Endocrinology and Metabolism
ISSN :
0021-972X
eISSN :
1945-7197
Publisher :
Endocrine Society, Chevy Chase, United States - Maryland
The Diabetes Control and Complication Trial Research Group. 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329:977-986.
Hirsch IB, Farkas-Hirsch R, Skyler JS. 1990 Intensive insulin therapy for treatment of type I diabetes. Diabetes Care. 13:1265-1283.
Skyler JS. 1989 Continuous subcutaneous insulin infusion (CSII) with external devices: current status. In: Ensminger WD, Selam JL, eds. Update in Drug Delivery Systems. Mount Kisco, NY: Futura; 163-183.
Bruttomesso D, Barberio S, Fongher C, et al. 1992 Retrospective analysis of daily glucose profile in type 1 diabetic patients with continuous subcutaneous insulin infusion (CSII). Diabet Res Clin Pract. 16:197-202.
Kitabchi AE, Fisher JN, Matteri R, Murphy MB. 1983 The use of continuous insulin delivery systems in treatment of diabetes mellitus. Ann Intern Med. 28:449-490.
Home PD, Marshall SM. 1984 Problems and safety of continuous subcutaneous insulin infusion. Diabetic Med. 1:41-44.
Castillo MJ, Scheen AJ, Lefèbvre PJ. 1995 Treatment with insulin infusion pumps and ketoacidotic episodes: From physiology to troubleshooting. Diabetes Metab Rev. 11:161-177.
Selam JL, Charles MA. 1990 Devices for insulin administration. Diabetes Care. 13:955-979.
Krzentowski G, Scheen A, Castillo M, Luyckx AS, Lefèbvre PJ. 1983 A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control. Diabetologia. 24:314-318.
Scheen A, Castillo M, Jandrain B, et al. 1984 Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. Diabetes Care. 7:338-342.
Lefèbvre PJ, Luyckx AS, Scheen AJ, Castillo M, Jandrain B, Krzentowski G. 1984 Conséquences métaboliques de la carence en insuline. In: J. Diabétologie Hotel Dieu. Paris: Flamarion Médecine-Sciences; 163-174.
Kraegen EW, Chisholm DG. 1985 Pharmacokinetics of insulin. Implications for continuous subcutaneous insulin infusion therapy. Clin Pharmacokinet. 10:303-314.
Scheen AJ. 1989 Pharmacocinétique de l'insuline administrée par voie souscutanée. Application au traitement par pompe portable. Diabete Metab. 15: 128-138.
Bergmann RN, Steil GM, Bradley DC, Watanabe RM. 1992 Modeling of insulin action in vivo. Annu Rev Physiol. 54:861-883.
Vaughan VJA, Rao RH, Kurtz AB, Buckell HM, Spathis GS. 1986 Strict nocturnal diabetic control diminishes subsequent glycemic escape during acute insulin withdrawal. Metabolism. 35:136-142.
Fanelli C, Pampanelli S, Epifano L, et al. 1994 Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia. 37:1265-1276.
Scheen AJ, Krzentowski G, Castillo M, Lefèbvre PJ, Luyckx AS. 1983 A 6 hour nocturnal interruption of a continuous subcutaneous insulin infusion. 2. Marked attenuation of the metabolic deterioration by somatostatin. Diabetologia. 24:319-325.
Castillo MJ, Scheen AJ, Gualda P, Lefèbvre PJ. 1989 Papel de la insulina y hormonas de la contra-regulación en las alteraciones metabólicas por deprivación de insulina en pacientes diabéticos. Rev Esp Fisiol. 45:53-60.
Scheen AJ, Gillet J, Rosenthaler J, et al. 1989 Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients. Diabetologia. 32:801-809.